Bronchial epithelial transcriptomics and experimental validation reveal asthma severity-related neutrophilc signatures and potential treatments

Qian Yan,Xinxin Zhang,Yi Xie,Jing Yang,Chengxin Liu,Miaofen Zhang,Wenjiang Zheng,Xueying Lin,Hui-ting Huang,Xiaohong Liu,Yong Jiang,Shao-feng Zhan,Xiufang Huang
DOI: https://doi.org/10.1038/s42003-024-05837-y
IF: 6.548
2024-02-14
Communications Biology
Abstract:Airway epithelial transcriptome analysis of asthma patients with different severity was used to disentangle the immune infiltration mechanisms affecting asthma exacerbation, which may be advantageous to asthma treatment. Here we introduce various bioinformatics methods and develop two models: an OVA/CFA-induced neutrophil asthma mouse model and an LPS-induced human bronchial epithelial cell damage model. Our objective is to investigate the molecular mechanisms, potential targets, and therapeutic strategies associated with asthma severity. Multiple bioinformatics methods identify meaningful differences in the degree of neutrophil infiltration in asthma patients with different severity. Then, PTPRC, TLR2, MMP9, FCGR3B, TYROBP, CXCR1, S100A12, FPR1, CCR1 and CXCR2 are identified as the hub genes. Furthermore, the mRNA expression of 10 hub genes is determined in vivo and in vitro models. Reperixin is identified as a pivotal drug targeting CXCR1, CXCR2 and MMP9. We further test the potential efficiency of Reperixin in 16HBE cells, and conclude that Reperixin can attenuate LPS-induced cellular damage and inhibit the expression of them. In this study, we successfully identify and validate several neutrophilic signatures and targets associated with asthma severity. Notably, Reperixin displays the ability to target CXCR1, CXCR2, and MMP9, suggesting its potential therapeutic value for managing deteriorating asthma.
biology
What problem does this paper attempt to address?
This paper attempts to address the issues of molecular mechanisms, potential therapeutic targets and treatment methods related to neutrophil infiltration in asthma, especially severe asthma. Specifically, the study reveals the mechanism of immune cell infiltration associated with asthma exacerbation, especially neutrophil infiltration, by analyzing the airway epithelial transcriptomes of asthma patients with different severities. This helps to discover new therapeutic targets and drugs to improve the treatment and management of asthma. The main objectives of the study include: 1. **Explore molecular mechanisms**: Identify significant differences in gene expression among asthma patients with different severities through multiple bioinformatics methods, especially genes related to neutrophil infiltration. 2. **Determine key genes**: Use methods such as weighted gene co - expression network analysis (WGCNA) to determine modules and key genes closely related to asthma severity and neutrophil infiltration. 3. **Verify key genes and drugs**: Establish an OVA/CFA - induced neutrophilic asthma mouse model and an LPS - induced human bronchial epithelial cell injury model to verify the functions of these key genes and test the efficacy of the candidate drug Reperixin. Ultimately, the study successfully identified and verified multiple neutrophil characteristics and targets related to asthma severity, especially the targeting effects of Reperixin on CXCR1, CXCR2 and MMP9, showing its potential therapeutic value in managing exacerbated asthma.